Therapy News and Research

RSS

Study highlights the impact of Reiki on pain, fatigue, and anxiety in cancer outpatients

A recent study conducted at University Hospitals Connor Whole Health has evaluated a Reiki program designed for outpatients with cancer and receiving infusion treatments at two University Hospitals infusion centers.

13 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

Potential new mRNA-based therapy for pre-eclampsia

Lipid nanoparticles targeting VEGF mRNA show promise in treating pre-eclampsia, restoring maternal blood pressure and enhancing fetal health in murine models.

13 Dec 2024

Key to LDL clearance uncovered: Structural details of apoB100-LDLR binding emerge

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL dimerization and potential treatments for familial hypercholesterolemia.

12 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Gene therapy to prevent stillbirth and premature delivery developed

Researchers investigate the effectiveness of placental nano-based insulin-like 1 growth factor gene therapy to correct fetal growth restriction.

12 Dec 2024

Addressing inequities in cardiovascular drug access

A new study assessing provincial and territorial variations in reimbursement criteria of drug coverage for patients covered by Canada's public pharmacare programs for two common cardiovascular conditions revealed significant inequities and deficiencies in access to medications and treatment.

12 Dec 2024

Harnessing exosomes to deliver therapeutic proteins

Researchers at The Ottawa Hospital and the University of Ottawa have discovered an 18-digit code that allows proteins to attach themselves to exosomes - tiny pinched-off pieces of cells that travel around the body and deliver biochemical signals.

11 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Therapy News and Research

Study highlights the impact of Reiki on pain, fatigue, and anxiety in cancer outpatients

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

Potential new mRNA-based therapy for pre-eclampsia

Key to LDL clearance uncovered: Structural details of apoB100-LDLR binding emerge

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

Gene therapy to prevent stillbirth and premature delivery developed

Addressing inequities in cardiovascular drug access

Harnessing exosomes to deliver therapeutic proteins

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

Next-generation cell-penetrating antibodies could transform cancer treatment

New class of antivirals shows promise against multiple viruses

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Prostate cancer vaccines: Progress, challenges, and future directions

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News